As of 2026-03-18, the EV/EBITDA ratio of Proteome Sciences PLC (PRM.L) is -14.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PRM.L's latest enterprise value is 21.07 mil GBP. PRM.L's TTM EBITDA according to its financial statements is -1.45 mil GBP. Dividing these 2 quantities gives us the above PRM.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 20.2x | 16.8x |
| Forward P/E multiples | 11.1x - 15.5x | 14.2x |
| Fair Price | (9.25) - (10.92) | (10.91) |
| Upside | -636.3% - -732.9% | -732.3% |
| Date | EV/EBITDA |
| 2026-03-16 | -14.64 |
| 2026-03-13 | -14.71 |
| 2026-03-12 | -14.57 |
| 2026-03-11 | -14.53 |
| 2026-03-10 | -14.62 |
| 2026-03-09 | -14.70 |
| 2026-03-06 | -14.77 |
| 2026-03-05 | -14.58 |
| 2026-03-04 | -14.65 |
| 2026-03-03 | -14.68 |
| 2026-03-02 | -14.79 |
| 2026-02-27 | -14.88 |
| 2026-02-26 | -14.75 |
| 2026-02-25 | -15.58 |
| 2026-02-24 | -15.48 |
| 2026-02-23 | -15.50 |
| 2026-02-20 | -15.39 |
| 2026-02-19 | -14.91 |
| 2026-02-18 | -14.85 |
| 2026-02-17 | -15.29 |
| 2026-02-16 | -15.02 |
| 2026-02-13 | -14.79 |
| 2026-02-12 | -14.64 |
| 2026-02-11 | -14.54 |
| 2026-02-10 | -14.73 |
| 2026-02-09 | -14.64 |
| 2026-02-06 | -14.82 |
| 2026-02-05 | -14.64 |
| 2026-02-04 | -14.76 |
| 2026-02-03 | -14.75 |
| 2026-02-02 | -14.92 |
| 2026-01-30 | -14.98 |
| 2026-01-29 | -15.22 |
| 2026-01-28 | -15.03 |
| 2026-01-27 | -15.16 |
| 2026-01-26 | -15.07 |
| 2026-01-23 | -18.29 |
| 2026-01-22 | -17.98 |
| 2026-01-21 | -17.62 |
| 2026-01-20 | -17.29 |
| 2026-01-19 | -18.88 |
| 2026-01-16 | -18.93 |
| 2026-01-15 | -18.81 |
| 2026-01-14 | -18.10 |
| 2026-01-13 | -18.24 |
| 2026-01-12 | -18.86 |
| 2026-01-09 | -18.22 |
| 2026-01-08 | -18.81 |
| 2026-01-07 | -18.71 |
| 2026-01-06 | -18.62 |